WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical ...
Shares of Gracell Biotechnologies GRCL have surged 62.3% in the one-week period compared with the industry’s breakeven growth. Zacks Investment Research Image Source: Zacks Investment Research The ...
Turning a patient’s cells into targeted cancer fighters presents manufacturing challenges that big pharmaceutical companies and upstart biotechs are trying to address. The cell therapy field is also ...
Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in rSLE, ...
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 7, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", Nasdaq: GRCL), a global clinical-stage biopharmaceutical ...
Gracell Bio stands to benefit from tax credits and marketing exclusivity following receipt of ‘orphan drug’ status for its CAR-T cancer treatment Analysts see profitability several years away as ...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (GRCL), a global clinical-stage biopharmaceutical company dedicated to developing ...
Oversubscribed transaction led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP, Exome Asset Management, Janus Henderson Investors, Logos Capital, OrbiMed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results